[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
July 4, 2007

Timing of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2007;298(1):37-38. doi:10.1001/jama.298.1.37-a

To the Editor: In the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Timing trial, Dr Stone and colleagues1 reported that more than 10% of patients developed thrombocytopenia, defined as a platelet count of less than 150 000/μL. Prior studies have defined thrombocytopenia as either less than 100 000/μL or at least a 25% decrease from baseline, with incidence ranging from 0.5% to 5.6%.2,3 It is unclear how many patients in the ACUITY trial developed significant thrombocytopenia using these alternative definitions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×